GE HealthCare Technologies Inc. (GEHC)

業務介紹

GE HealthCare Technologies Inc.（GE醫療科技公司）從事於美國、加拿大、歐洲、中東、非洲、中國、台灣、蒙古、香港和國際市場的產品、服務和相關數位解決方案的開發、製造和營銷，用於診斷、治療和監測患者。該公司通過四個業務板塊運營：影像、超聲波、病患護理解決方案和藥物診斷。影像板塊提供分子影像、電腦斷層掃描、磁共振成像、影像引導治療和X光系統，以及婦科健康產品。超聲波板塊提供篩查、診斷、治療和監測某些疾病的放射學和初級護理、婦科、心血管以及即時護理和手持式超聲波解決方案，以及外科視覺化和引導產品。病患護理解決方案板塊提供通過病患監測、麻醉傳遞和呼吸護理、診斷心臟病和母嬰護理產品的醫療設備、消耗品、服務和數位解決方案。藥物診斷板塊供應診斷劑，包括CT、血管攝影和X光、MR、單光子發射計算機斷層掃描、正子發射計算機斷層掃描和超聲波，供放射學和核醫學行業使用。該板塊還提供對比介質藥物，用於在影像檢查期間增加組織或結構的可見性之前給患者注射；以及分子影像劑，或放射性藥物，這些分子示踪劑標記有放射性同位素，注射到患者體內進行診斷影像掃描之前。該公司成立於2022年，總部位於伊利諾伊州芝加哥。

GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, Europe, the Middle East, Africa, China, Taiwan, Mongolia, Hong Kong, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, image-guided therapy, and X-ray systems, as well as women's health products. The Ultrasound segment provides screening, diagnosis, treatment, and monitoring of certain diseases through radiology and primary care, women's health, cardiovascular, and point of care and handheld ultrasound solutions, as well as surgical visualization and guidance products. The Patient Care Solutions segment involved in the provision of medical devices, consumable products, services, and digital solutions through patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, and maternal infant care products. The Pharmaceutical Diagnostics supplies diagnostic agents, including CT, angiography and X-ray, MR, single-photon emission computed tomography, positron emission tomography, and ultrasound to the radiology and nuclear medicine industry. The segment also provides contrast media pharmaceuticals, administered to a patient prior to certain diagnostic scans to increase the visibility of tissues or structures during imaging exams; and molecular imaging agents, or radiopharmaceuticals, which are molecular tracers labeled with radioisotopes that are injected into a patient prior to a diagnostic imaging scan. The company was incorporated in 2022 and is headquartered in Chicago, Illinois.

公司網址

https://www.gehealthcare.com